GEC-ESTRO survey of 106Ru eye applicator practice for ocular melanoma – Physicist survey

Marisol De Brabandere; Elisa Placidi; Frank-André Siebert; Åsa Carlsson Tedgren; Andrea Slocker Escarpa; Luca Tagliaferri; Michael Andrássy; Carmen Schulz; Lotte S. Fog

doi:10.1016/j.radonc.2024.110114

journal article Apr 01, 2024

GEC-ESTRO survey of 106Ru eye applicator practice for ocular melanoma – Physicist survey

Marisol De Brabandere Elisa Placidi Frank-André Siebert Åsa Carlsson Tedgren Andrea Slocker Escarpa Luca Tagliaferri

Michael Andrássy Carmen Schulz Lotte S. Fog

Radiotherapy and Oncology Vol. 193 pp. 110114 · Elsevier BV

View at Publisher Save 10.1016/j.radonc.2024.110114

Topics

No keywords indexed for this article. Browse by subject →

References

28

[1]

GEC-ESTRO handbook of brachytherapy, 2nd edition, Chapter 31: Uveal melanoma. 2020.

[2]

Lommatzsch "Treatment of choroidal melanomas with 106Ru/106Rh beta-ray applicators" Surv Ophthalmol (1974)

[3]

Cohen G, Lovelock M, Amols H et al. Dosimetric analysis of ruthenium-106 ophthalmic applicators for the treatment of retinoblastoma and ocular melanoma. Proceedings of the 22nd Annual International Conference of the IEEE Engineering in Medicine and Biology Society (Cat. No.00CH37143), IEEE, 2000: 2757–2760. doi: 10.1109/IEMBS.2000.901432. 10.1109/iembs.2000.901432

[4]

Damato "Visual acuity after Ruthenium106 brachytherapy of choroidal melanomas" Int J Radiat Oncol Biol Phys (2005) 10.1016/j.ijrobp.2005.02.059

[5]

Seregard "Long-term survival after ruthenium plaque radiotherapy for uveal melanoma. A meta-analysis of studies including 1066 patients" Acta Ophthalmol Scand (1999)

[6]

Hansen "A convex windowless extrapolation chamber to measure surface dose rate from 106 Ru/106 Rh episcleral plaques" Med Phys (2019) 10.1002/mp.13488

[7]

Nag "The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas" Int J of Radiat Oncol Biol Phys (2003) 10.1016/s0360-3016(03)00006-3

[8]

Collaborative Ocular Melanoma Study (COMS) Group. The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006; 124(12): 1684-1693. doi: 10.1001/archopht.124.12.1684. 10.1001/archopht.124.12.1684

[9]

Simpson "The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma" Brachytherapy (2014) 10.1016/j.brachy.2013.11.008

[10]

Chiu-Tsao "Dosimetry of 125 I and 103 Pd COMS eye plaques for intraocular tumors: Report of Task Group 129 by the AAPM and ABS" Med Phys (2012) 10.1118/1.4749933

[11]

Thomson "AAPM recommendations on medical physics practices for ocular plaque brachytherapy: Report of task group 221" Med Phys (2020) 10.1002/mp.13996

[12]

International Organization for Standardization. Clinical dosimetry: Beta radiation sources for brachytherapy (ISO 21439). 2009. https://www.iso.org/obp/ui/en/#iso:std:iso:21439:ed-1:v1:en.

[13]

Perez-Calatayud "GEC-ESTRO ACROP recommendations on calibration and traceability of LE-LDR photon-emitting brachytherapy sources at the hospital level" Radiother Oncol (2019) 10.1016/j.radonc.2019.02.008

[14]

Perez-Calatayud "GEC-ESTRO ACROP recommendations on calibration and traceability of HE HDR-PDR photon-emitting brachytherapy sources at the hospital level" Radiother Oncol (2022) 10.1016/j.radonc.2022.09.012

[15]

DIN:6803-2:2020-12. Dosimetry for Photon Brachytherapy - Part 2: Radiation sources, source calibration, source test and dose calculation. 2020.

[16]

Nath R, Anderson LL, Meli JA et al. Code of practice for brachytherapy physics: Report of the AAPM Radiation Therapy Committee Task Group No. 56. Med Phys 1997; 24(10): 1557–1598. doi: 10.1118/1.597966. 10.1118/1.597966

[17]

IAEA-TECDOC-1274. Calibration of photon and β ray sources used in brachytherapy. 2002.

[18]

Pötter "Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy—3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology" Radiother Oncol (2005) 10.1016/j.radonc.2005.11.014

[19]

Hoskin "GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: An update" Radiother Oncol (2013) 10.1016/j.radonc.2013.05.002

[20]

Strnad "ESTRO-ACROP guideline: Interstitial multi-catheter breast brachytherapy as Accelerated Partial Breast Irradiation alone or as boost – GEC-ESTRO Breast Cancer Working Group practical recommendations" Radiother Oncol (2018) 10.1016/j.radonc.2018.04.009

[21]

Espensen "Tumour control probability after Ruthenium-106 brachytherapy for choroidal melanomas" Acta Oncol (2020) 10.1080/0284186x.2020.1762925

[22]

Quivey JM, Augsburger J, Snelling L et al. 125I plaque therapy for uveal melanoma: Analysis of the impact of time and dose factors on local control. Cancer 1996; 77(11): 2356–2362. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2356::AID-CNCR26>3.0.CO;2-V. 10.1002/(sici)1097-0142(19960601)77:11<2356::aid-cncr26>3.0.co;2-v

[23]

Naseripour "Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate" J Contemp Brachyther (2016) 10.5114/jcb.2016.57818

[24]

Gagne "BEDVH-A method for evaluating biologically effective dose volume histograms: Application to eye plaque brachytherapy implants" Med Phys (2012) 10.1118/1.3679010

[25]

Gagne "Radiobiology for eye plaque brachytherapy and evaluation of implant duration and radionuclide choice using an objective function" Med Phys (2012) 10.1118/1.4718683

[26]

Tagliaferri et al, Pagliara MM, Boldrini L et al. INTERACTS (INTErventional Radiotherapy ACtive Teaching School) guidelines for quality assurance in choroidal melanoma interventional radiotherapy (brachytherapy) procedures. J Contemp Brachytherapy 2017; 9(3): 287–295. doi: 10.5114/jcb.2017.68761. 10.5114/jcb.2017.68761

[27]

Stöckel "Dose distributions and treatment margins in ocular brachytherapy with 106Ru eye plaques" Ocul Oncol Pathol (2018) 10.1159/000479558

[28]

Heilemann "Treatment plan optimization and robustness of 106Ru eye plaque brachytherapy using a novel software tool" Radiother Oncol (2017) 10.1016/j.radonc.2017.01.010

Metrics

6

Citations

28

References

Details

Published: Apr 01, 2024
Vol/Issue: 193
Pages: 110114
License: View

Authors

M

Marisol De Brabandere

Department of Oncology Pathology Karolinska Institute Stockholm Sweden; Department of Nuclear Medicine and Medical Physics Karolinska University Hospital Stockholm Sweden; Department of Health, Medicine and Caring Sciences Linköping University Linköping Sweden

A

Andrea Slocker Escarpa

Cite This Article

Marisol De Brabandere, Elisa Placidi, Frank-André Siebert, et al. (2024). GEC-ESTRO survey of 106Ru eye applicator practice for ocular melanoma – Physicist survey. Radiotherapy and Oncology, 193, 110114. https://doi.org/10.1016/j.radonc.2024.110114

GEC-ESTRO survey of 106Ru eye applicator practice for ocular melanoma – Physicist survey

You May Also Like